NCT06222489View on ClinicalTrials.gov

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

PHASE2RecruitingINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

May 1, 2027

Study Completion Date

May 1, 2028

Conditions
Non-Small Cell Lung CarcinomaAdvanced Non-Small Cell Squamous Lung CancerEGFR Gene Mutation
Interventions
DRUG

89Zr-Patritumab deruxtecan

Day 1, day 3, day 6, day 11 and day 26 of first course

Trial Locations (1)

1066CX

RECRUITING

Antoni van Leeuwenhoek, Amsterdam

Sponsors

Collaborators (1)

Daiichi Sankyo
All Listed Sponsors
collaborator

Daiichi Sankyo

INDUSTRY

lead

The Netherlands Cancer Institute

OTHER

NCT06222489 - Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT | Biotech Hunter | Biotech Hunter